MAPK1 and cancer: Despite the therapeutic effectiveness of MAPK inhibitors, cancer cells develop chemoresistance that needs to be targeted via bypassing several molecular signaling points, pairing MAPK inhibitors with multiple immune agents and targeting the MAPK pathway downstream of ERK to prevent its reactivation mechanisms using combination therapies, downstream signaling regulators and PROTACs.